Platelets in the pathogenesis of solid tumors
Authors:
Beatrix Bencsiková 1,2; Kristína Greplová 2*; Kateřina Pilátová 2,3; Zuzana Volejníková 2; Dalibor Valík 2,3; Giannoula Lakka Klement 3,4; Lenka Zdražilová-Dubská 2,3
Authors‘ workplace:
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
1; Oddělení laboratorní medicíny, Masarykův onkologický ústav, Brno
2; Regionální centrum aplikované molekulární onkologie, Masarykův onkologický ústav, Brno
3; Center of Cancer Systems Biology, Steward St. Elizabeth’s Medical Center Pediatric Hematology Oncology, Tufts University School of Medicine, Boston, MA, USA
4
Published in:
Čas. Lék. čes. 2014; 152: 78-85
Category:
Review Article
* přispěly stejně
Overview
Cancer cells trigger platelet aggregation. Reciprocally, platelet aggregation promotes tumor growth and metastasis. Within the tumor microenvironment, platelet regulates tumor growth via several mechanisms involving stimulation of angiogenesis, inflammation, coagulation, and stabilizing of vessel wall. In circulation, cancer cells coated by platelets can travel to metastatic site protected from intravascular shear forces and from immune surveillance. Finally, platelets facilitate adhesion of tumor cells and formation of the metastatic niche. Platelet-derived microparticles contain growth factors contributing to tumor angiogenesis. On the other hand, platelets can selectively release anti-angiogenic factors in a process connected to tumor dormancy. Therapeutical inhibition of platelet aggregation prevents tumor development in certain tumor types and may contribute to better cancer outcome.
Keywords:
blood platelets – neoplasms – angiogenesis – platelet aggregation – platelet aggregation inhibitors – tumor microenvironment – aspirin – coagulation
Sources
1. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. The Lancet Oncology 2002; 3(7): 425–430.
2. Trousseau A. Phlegmatia alba dolens. Clinique Medicale De L’Hotel-Dieu de Paris. 1865; 3: 654–712.
3. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Nat Acad Sci USA 1968; 61: 46–52.
4. Jurasz P, Alonso-Escolano D, Radomski MW. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J. Pharmacol 2004; 143(7): 819–826.
5. Karpatkin S, Pearlstein E, Ambrogio C, Coller BS. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1988; 81(4): 1012–1019.
6. Karpatkin S, Ambrogio C, Pearlstein E. The role of tumor-induced platelet aggregation, platelet adhesion and adhesive proteins in tumor metastasis. Prog Clin Biol Res 1988; 283: 585–606.
7. Holmes CE, Huang JC, Pace TR, Howard AB, Muss HB. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer. Clin Cancer Res 2008; 14(10): 3070–3076.
8. Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Fox L, Klement GL, Folkman J. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol 2010; 85(7): 487–493.
9. Italiano JE Jr, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet α-granules and differentially released. Blood 2008; 111(3): 1227–1233.
10. Manegold PC, Hutter J, Pahernik SA, Messmer K, Dellian M. Plate-let-endothelial interaction in tumor angiogenesis and microcirculation. Blood 2003; 101(5): 1970–1976.
11. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009; 27(29): 4839–4847.
12. Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol 2009; 27(29): 4821–4826.
13. Tranum BL, Haut A. Thrombocytosis: platelet kinetics in neoplasia.J Lab Clin Med 1974; 84(5): 615–619.
14. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002; 9(3): 287–291.
15. Monreal M, Fernandez-Llamazares J, Piñol M, Julian JF, Broggi M, Escola D, Abad A. Platelet count and survival in patients with colorectal cancer – a preliminary study. Thromb Haemost 1998; 79(5): 916–918.
16. Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000; 86(3): 203–207.
17. Gücer F, Moser F, Tamussino K, Reich O, Haas J, Arikan G, Petru E, Winter R. Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol 1998; 70(2): 210–214.
18. Menczer J, Schejter E, Geva D, Ginath S, Zakut H. Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. Eur J Gynaecol Oncol 1998; 19(1): 82–84.
19. Lopes A, Daras V, Cross PA, Robertson G, Beynon G, Monaghan JM. Thrombocytosis as a prognostic factor in women with cervical cancer. Cancer 1994; 74(1): 90–92.
20. Zeimet AG, Marth C, Müller-Holzner E, Daxenbichler G, Dapunt O. Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1994; 170(2): 549–554.
21. Estrov Z, Talpaz M, Mavligit G, Pazdur R, Harris D, Greenberg SM, Kurzrock R. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med 1995; 98(6): 551–558.
22. Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E, Dirix LY. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999; 80(5–6): 892–897.
23. Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, Bander NH, Rubin SC. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patiens with epithelial ovarian cancer. Br J Haematol 1993; 83(3): 433–441.
24. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H.Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001; 98(9): 2720–2725.
25. Suzuki A, Takahashi T, Nakamura K, Tsuyuoka R, Okuno Y, Enomoto T, Fukumoto M, Imura H. Thrombocytosis in patients with tumors producing colony-stimulating factor. Blood 1992; 80(8): 2052–2059.
26. Suzuki A, Takahashi T, Okuno Y, Tsuyuoka R, Fukumoto M, Nakamura K, Imura H. IL-1 production as a regulator of G-CSF and IL-6 production in CSF-producing cell lines. Br J Cancer 1992; 65(4): 515–518.
27. Dymicka-Piekarska V, Kemona H, Guzinska-Ustymowicz K. Does surgery affect certain mediators of thrombocytopoiesis in patients with colorectal cancer? Hepatogastroenterology 2007; 54(77): 1407–1411.
28. dos Santos Silva I, De Stavola BL, Pizzi C, Meade TW. Circulating levels of coagulation and inflammation markers and cancer risks: individual participant analysis of data from three long-term cohorts. Int J Epidemiol 2010; 39(3): 699–709.
29. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, van Dam P, Prové A, Lemmens J, Vermeulen P. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86(3): 389–395.
30. Lippi G, Franchini M, Biasiutti C, Dellagiacoma G, Salvagno GL, Guidi GC. Increased D-dimer value and occult cancer in the absence of detectable thrombosis. Haematologica 2007; 92(4): 53–55.
Další citace u autorky.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Some immunological properties of female saliva and its effect on sperm motility
- Platelets in the pathogenesis of solid tumors
- Potential interactions between drugs and dietary supplements
- Circulating tumor cells and prostate cancer prognosis